CHICAGO — In this video, Clement K. Chan, MD, FACS, recaps a lecture from the Macula Society symposium at the AAO meeting.In the Arnall Patz Lecture, Richard F. Spaide, MD, discussed advancements in modern OCT technology that allow for the measurement …
Author: Healio ophthalmology
FDA clears Epithelial Thickness Module for Anterion imaging platform
The FDA cleared the Epithelial Thickness Module for the Anterion cornea app from Heidelberg Engineering, according to a press release.“Anterion technology stands out in the global market by offering the most data points and, consequently, the lowest le…
Q&A: Expert offers tips on how to grow your brand, practice with social media
Healio spoke with an expert about the importance of social media, why physicians should utilize it and the do’s and don’ts behind this growing form of communication.When thinking about the type of content posted on social media, some of the first thing…
Woman presents with bilateral floaters, foggy vision
A 53-year-old woman presented to an outside provider with 1 day of bilateral floaters and “smoke/foggy” vision.She had a medical history of Graves’ disease on daily levothyroxine and breast cancer treated with chemotherapy, radiation and mastectomy. Sh…
Variety of scleral fixation techniques can replace or rescue IOL
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.This month we are going to discuss scleral fixation a…
Skill needed for challenging staging, treatment of ROP
Retinopathy of prematurity occurs primarily in low birth weight premature infants who are admitted to a neonatal intensive care unit and require oxygen supplementation.Current teaching is that either too much or too little oxygen can result in ROP. ROP…
Roundtable addresses ROP screening, fellowship training efforts
A study published in 2023 that analyzed more than 23 million births found that the proportion of premature infants diagnosed with retinopathy of prematurity nearly doubled in the U.S. from 2003 to 2019.Led by Section Editor Robert S. Gold, MD, Healio |…
Pediatric ophthalmologists review how to address vision therapy with parents
Optometrists sometimes suggest vision therapy to improve visual skills, addressing perceptual vision and myopia.However, no scientific evidence currently suggests that behavioral vision therapy is beneficial or can definitively improve myopia, accordin…
New Year’s resolutions for 2025
Happy New Year! How was your holiday season?As usual, I am sitting down to write this column long before any of the stuff I am asking about has actually happened for me. It is 19 degrees in Cleveland today, and Lake Erie is a roiling cauldron of season…
Management of macular telangiectasia type 2 may be near
Macular telangiectasia type 2 is a progressive and relatively rare neurodegenerative disease of the macula that typically affects patients who are older than 40 years of age, more predominantly women.Initially, macular telangiectasia (MacTel) type 2 wa…
Fluorescein pooling effect assists late lifting of LASIK flaps
A quick look at ChatGPT tells me that there have been few reports of “late lifting” after LASIK.The best article is referenced, and the actual technique for late lifting is described, but the most difficult part is identifying the flap margin, and I wi…
Evolution of AI in ophthalmology
Throughout history, all medical decision-making has relied upon anecdote, expert opinion, and cumbersome and limited clinical trials with delayed or nonexistent post hoc analysis and validation.More recently with the advent of large, connected datasets…
Retinitis pigmentosa therapy receives rare pediatric disease designation
The FDA granted rare pediatric disease designation to VG901 for the treatment of retinitis pigmentosa caused by mutations in the CNGA1 gene, according to a press release from ViGeneron.The designation allows the company to receive a priority review vou…
VIDEO: Avoid IOP ‘peaks and troughs’ by using stand-alone canal-based MIGS
NEW YORK — In this presentation from OSN New York, Manjool M. Shah, MD, discusses why stand-alone canal-based MIGS is an alternative to topical medications for glaucoma treatment.According to Shah, even when patients adhere to topical therapy, there ar…
Canyon Labs acquires iuvo BioScience’s lab, consulting services
Canyon Labs announced the strategic acquisition of iuvo BioScience’s laboratory services and scientific consulting divisions, according to a press release.The acquisition “positions Canyon Labs to deliver comprehensive end-to-end solutions in pharmaceu…
Healio Community, new engagement platform, aims to foster professional connection
Healio has launched the Healio Community platform to empower and connect professionals in health care.Health care professionals must navigate intense workloads and demanding schedules, which can leave them feeling isolated, Healio said in a press relea…
VIDEO: Expert offers treatment guidelines for proliferative diabetic retinopathy
NEW YORK — In this presentation from OSN New York Retina, Carl D. Regillo, MD, of Wills Eye Hospital, provides guidelines for the treatment of proliferative diabetic retinopathy.Regillo discussed treatment with panretinal photocoagulation vs. anti-VEGF…
VIDEO: Thyroid eye disease has inflammatory mimics
NEW YORK — In this presentation from OSN New York Retina, Nicholas Mahoney, MD, discusses thyroid eye disease.Mahoney said thyroid eye disease is an orbital inflammatory disorder, and a few other conditions mimic its effect on patients, including infec…
Aviceda raises $207.5 million in Series C funding to advance geographic atrophy program
Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic atrophy, according to a press release.Omega Funds and TCGX led the financing round. Contributors included Enavate Sciences, Jeito Capital, Bl…
VIDEO: Real-world faricimab data consistent with clinical trials
NEW YORK — In this presentation from OSN New York Retina, Ferhina S. Ali, MD, MPH, discusses how real-world experience with new anti-VEGF therapies is measuring up to what was seen in clinical trials.She said real-world outcomes are generally poorer th…